Auten Quoted in Law360 Article on Reused PTAB Positions
Taft Pharmaceutical & Life Sciences Chair Stephen Auten is quoted in the Feb. 8 Law360 article "USPTO's Take on Reused PTAB Positions May Upend Strategy." The article focuses on the USPTO's amicus brief in support of the position that a successful IPR defense should be barred at trial.
Auten states “The impact would be particularly strong for generic-drug makers, who must prevail in a district court patent case in order to get approval for their abbreviated new drug applications.”
In This Article
You May Also Like
Five Taft Intellectual Property Attorneys Named to 2021 WTR 1000 Wright Provides Pro Bono Trademark Services to Go In Your Purse For A Nurse